221 related articles for article (PubMed ID: 34106450)
1. Cost-Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand.
Deerochanawong C; Vareesangthip K; Piyayotai D; Thongsuk D; Pojchaijongdee N; Permsuwan U
Diabetes Ther; 2021 Jul; 12(7):1947-1963. PubMed ID: 34106450
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction.
Krittayaphong R; Permsuwan U
Int J Cardiol; 2021 Jan; 322():183-190. PubMed ID: 32800910
[TBL] [Abstract][Full Text] [Related]
3. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
Abushanab D; Chbib S; Kaddoura R; Al Hail M; Abdul Rouf PV; El Kassem W; Shah J; Ravindran Nair RK; Al-Badriyeh D
J Med Econ; 2024; 27(1):404-417. PubMed ID: 38390641
[TBL] [Abstract][Full Text] [Related]
4. Cost-Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand.
Vareesangthip K; Deerochanawong C; Thongsuk D; Pojchaijongdee N; Permsuwan U
Adv Ther; 2022 Mar; 39(3):1279-1292. PubMed ID: 35038121
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China.
Yao Y; Zhang R; An T; Zhao X; Zhang J
ESC Heart Fail; 2020 Dec; 7(6):3582-3592. PubMed ID: 33107212
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study.
Escobar C; Morales C; Capel M; Simón S; Pérez-Alcántara F; Pomares E
BMC Health Serv Res; 2022 Feb; 22(1):217. PubMed ID: 35177053
[TBL] [Abstract][Full Text] [Related]
7. Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction.
Krittayaphong R; Permsuwan U
Am J Cardiovasc Drugs; 2022 Sep; 22(5):577-590. PubMed ID: 35796952
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China.
Huang K; Wang Y; Sun S; Zhu Q; Zhou W; Liu J; Zhu D; Xie X
Front Public Health; 2022; 10():936703. PubMed ID: 35910934
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China.
Jiang Y; Zheng R; Sang H
Front Pharmacol; 2021; 12():733681. PubMed ID: 34858172
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsimihodimos V; Diogo V; Karpouzos G; Papageorgiou G; Kourlaba G
Clin Drug Investig; 2021 Apr; 41(4):371-380. PubMed ID: 33687695
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States.
Nechi RN; Rane A; Karaye RM; Ndikumukiza C; Alsahali S; Jatau AI; Zoni CR; Alanzi A; Karaye IM; Yunusa I
Clin Ther; 2023 Jul; 45(7):627-632. PubMed ID: 37270374
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
[TBL] [Abstract][Full Text] [Related]
13. Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand.
Deerochanawong C; Krittayaphong R; Romano JGU; Rhee NA; Permsuwan U
Diabetes Ther; 2023 Mar; 14(3):531-552. PubMed ID: 36719606
[TBL] [Abstract][Full Text] [Related]
14. A cost-effectiveness analysis of linagliptin add-on to insulin treatment for patients with type 2 diabetes mellitus and chronic kidney disease in Iran.
Fariman SA; Nosrati M; Rahmani P; Nikfar S
J Diabetes Metab Disord; 2023 Dec; 22(2):1263-1271. PubMed ID: 37975115
[TBL] [Abstract][Full Text] [Related]
15. Cost-Utility Analysis of Transcatheter Aortic Valve Implantation versus Surgery in High-Risk Severe Aortic Stenosis Patients in Thailand.
Permsuwan U; Yoodee V; Buddhari W; Wongpraparut N; Thonghong T; Cheewatanakornkul S; Meemook K; Sakiyalak P; Duangpakdee P; Yadee J
Clinicoecon Outcomes Res; 2022; 14():487-498. PubMed ID: 35909499
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
18. Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan.
Kodera S; Morita H; Nishi H; Takeda N; Ando J; Komuro I
Circ J; 2022 Nov; 86(12):2021-2028. PubMed ID: 36070962
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction.
Parizo JT; Goldhaber-Fiebert JD; Salomon JA; Khush KK; Spertus JA; Heidenreich PA; Sandhu AT
JAMA Cardiol; 2021 Aug; 6(8):926-935. PubMed ID: 34037681
[TBL] [Abstract][Full Text] [Related]
20. Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers.
Yu X; Hao Y; Zhu Z; Zhang W; Liu B; Ma M; Zhang X; Wei N; Wang J; Liu F
Clin Drug Investig; 2023 Apr; 43(4):241-250. PubMed ID: 36929485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
